Zobrazeno 1 - 10
of 234
pro vyhledávání: '"Shaodong Hong"'
Autor:
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and
Externí odkaz:
https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899
Autor:
Yihua Huang, Yuanyuan Zhao, Yan Huang, Yunpeng Yang, Yaxiong Zhang, Shaodong Hong, Hongyun Zhao, Shen Zhao, Ting Zhou, Gang Chen, Huaqiang Zhou, Yuxiang Ma, Ningning Zhou, Li Zhang, Wenfeng Fang
Publikováno v:
MedComm, Vol 5, Iss 5, Pp n/a-n/a (2024)
Abstract There remains an unmet need for targeted therapies against advanced non‐small‐cell lung cancer (NSCLC) with HER2 mutations. To improve the antitumor activity of single anti‐HER2 agent, this prospective, single‐arm clinical trial (NCT
Externí odkaz:
https://doaj.org/article/51d9fc46249d4a59a8f3f6ab7dbe7aa1
Autor:
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 14, Iss 34, Pp 3421-3429 (2023)
Abstract Immune checkpoint inhibitors (PD‐1/PD‐L1 and CTLA‐4 blockade) have revolutionized the treatment landscape in non‐small cell lung cancer (NSCLC). Secondary resistance to immunotherapy (IO), which poses a substantial challenge in clini
Externí odkaz:
https://doaj.org/article/bdd49d5369d24d70bad9a053f8310938
Autor:
Anlin Li, Linfeng Luo, Wei Du, Zhixin Yu, Lina He, Sha Fu, Yuanyuan Wang, Yixin Zhou, Chunlong Yang, Yunpeng Yang, Wenfeng Fang, Li Zhang, Shaodong Hong
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Programmed cell death ligand 1 (PD-L1) expression remains the most widely used biomarker for predicting response to immune checkpoint inhibitors (ICI), but its predictiveness varies considerably. Identification of factors accounting for the
Externí odkaz:
https://doaj.org/article/d844aac406404207a7c41966a3d862f5
Autor:
Wael A. S. Ali MD, PhD, Xinxin Huang MD, Yuehan Wu MD, Yuxiang Ma MD, PhD, Hui Pan MD, PhD, Jun Liao MD, Zhang Yang MD, Shaodong Hong MD, PhD, Yunpeng Yang MD, PhD, Yan Huang MD, PhD, Yuanyuan Zhao MD, PhD, Wenfeng Fang MD, PhD, Hongyun Zhao MD, PhD, Li Zhang MD, PhD
Publikováno v:
Cancer Control, Vol 30 (2023)
Background We aimed to investigate the determinant factors of anti-PD-1 therapy outcome in nasopharyngeal carcinoma (NPC). Methods In this retrospective study, we included 64 patients with recurrent/metastatic NPC. The association of patients’ char
Externí odkaz:
https://doaj.org/article/a911108dd2e84eeb97ffd9123c64f072
Autor:
Yi‐Long Wu, Shun Lu, Qinghua Zhou, Li Zhang, Ying Cheng, Jie Wang, Buhai Wang, Chengping Hu, Lizhu Lin, Wenzhao Zhong, Yong Song, Nong Yang, Xiaorong Dong, Jian Zhao, Haihong Yang, Hui Guo, Xiaolong Yan, Hongxu Liu, Rui Ma, Jie Lin, Siyang Liu, Chun Chen, Lifeng Wang, Chengzhi Zhou, Ming Zhou, Fang Wu, Xue‐Ning Yang, Yingying Du, Yu Yao, Yang Shao, Shaodong Hong, Jiuwei Cui, Xueping Quan, Rongrong Chen, Jiayan Wu, Jiatao Zhang, Jianya Zhou, Binchao Wang, Chao Cheng, Huijuan Wang, Jingjing Liu, Lin Wu, Yan Huang, Yukun Kuang, Yongchang Zhang, Jia Hu, Jinji Yang, Weineng Feng, Wenmei Su, Yun Fan, Fan Yang, Ming Chen, Kejing Tang, Yi Pan, Peng Shen, Anwen Liu, Haibo Zhang, Wenhua Liang, Qing Zhou, Zhiyong Ma, Xiuyu Cai, Hui Liu, Longfei Chen, Shaokun Chuai, Jianzhen Shan, Yanfang Zheng, Changxuan You, Xiaoxia Zhu, Li Li, Tongmei Zhang, Haiyan Tu, Wurong Lin, Xuchao Zhang, Penghui Zhou, Zunfu Ke, Huiying Liang
Publikováno v:
Medicine Advances, Vol 1, Iss 1, Pp 3-13 (2023)
Abstract Stage III non‐small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation
Externí odkaz:
https://doaj.org/article/628a61c2e0b7401888cbceb96adb32ce
Autor:
Li-Na He, Tao Chen, Sha Fu, Yongluo Jiang, Xuanye Zhang, Chen Chen, Wei Du, Linfeng Luo, Anlin Li, Yixing Wang, Hui Yu, Yixin Zhou, Yuhong Wang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Wenfeng Fang, Li Zhang, Shaodong Hong
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: For Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1), measuring up to two target lesions per organ is an arbitrary criterion. Objectives: We sought to compare response assessment using RECIST1.1 and modified RECIST1.1
Externí odkaz:
https://doaj.org/article/b7a1963657ab463bae02eb2f78a4c360
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
The IMpower010 and KEYNOTE-091 trials have demonstrated the benefit of adjuvant immunotherapy (IO) after chemotherapy (C+IO) in resected non-small cell lung cancer (NSCLC), including those with epidermal growth factor receptor gene (EGFR) mutation. M
Externí odkaz:
https://doaj.org/article/987eddf1d20045ada20d122b61e9af88
Autor:
Li-Na He, Haifeng Li, Wei Du, Sha Fu, Linfeng luo, Tao Chen, Xuanye Zhang, Chen Chen, Yongluo Jiang, Yixing Wang, Yuhong Wang, Hui Yu, Yixin Zhou, Zuan Lin, Yuanyuan Zhao, Yan Huang, Hongyun Zhao, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong
Publikováno v:
iScience, Vol 26, Iss 7, Pp 107058- (2023)
Summary: The immune and stromal contexture within the tumor microenvironment (TME) interact with cancer cells and jointly determine disease process and therapeutic response. We aimed at developing a risk scoring model based on TME-related genes of sq
Externí odkaz:
https://doaj.org/article/9435e0cd9f3d4bc2850761808524bced
Autor:
Yixing Wang, Sha Fu, Xuanye Zhang, Wei Du, Linfeng Luo, Yongluo Jiang, Yixin Zhou, Yuanyuan Zhao, Yunpeng Yang, Hongyun Zhao, Wenfeng Fang, Yan Huang, Li Zhang, Shaodong Hong
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveFew data are available on the optimal treatment options after disease progression from first-line treatment of immune checkpoint inhibitors (ICIs) plus chemotherapy. This study aimed to describe the safety and efficacy of continuing ICIs bey
Externí odkaz:
https://doaj.org/article/fa9994008bec41ff92f730379f8bb2a9